22 Oct 2026PharmacologyAntineoplastic Agents
A 62-year-old male with a history of recurrent B-cell non-Hodgkin lymphoma is scheduled to begin a new targeted therapy regimen. The selected agent is a chimeric murine/human monoclonal IgG1 antibody that specifically binds to the CD20 surface antigen, inducing B-cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Which of the following drugs represents this specific monoclonal antibody?
Tap an option to check your answer.